Determination of a suitable voriconazole pharmacokinetic model for personalised dosing
- 578 Downloads
Model based personalised dosing (MBPD) is a sophisticated form of individualised therapy, where a population pharmacokinetic (PK) or pharmacodynamic model is utilised to estimate the dose required to reach a target exposure or effect. The choice of which model to implement in MBPD is a subjective decision. By choosing one model, information from the remaining models is ignored, as well as the rest of the literature base. This manuscript describes a methodology to develop a ‘hybrid’ model for voriconazole that incorporated information from prior models in a biologically plausible manner. Voriconazole is a triazole antifungal with difficult to predict PK, although it does have a defined exposure–response relationship. Nine population PK models of voriconazole were identified from the literature. The models differed significantly in structural components. The hybrid model contained a two-compartment disposition model with mixed linear and nonlinear time-dependent clearance. The parameters for the hybrid model were determined using simulation techniques. Validation of the hybrid model was assessed via visual predictive checks, which indicated the majority of the variability in the literature models was captured by the hybrid model. The predictive performance was assessed using four different sampling strategies of limited concentrations from ten richly PK sampled subjects to predict future concentrations. Overall, the hybrid model predicted future concentrations with good precision. Further prospective and retrospective validation of the hybrid model is required before it could be used in clinical practice.
KeywordsPersonalised medicine Voriconazole Bayesian dose forecasting Model based personalised dosing Dose individualisation
D.A.J.M. is supported by an Australian Postgraduate Award.
Compliance with ethical standards
Conflict of interest
B.G. and J.M. declare no conflicts of interest. E.G.P. is a member of the Antifungal Advisory Boards of Pfizer and Merck.
- 2.Jelliffe R, Neely M, Schumitzky A, Bayard D, Van Guilder M, Botnen A, Bustad A, Laing D, Yamada W, Bartroff J, Tatarinova T (2011) Nonparametric population modeling and Bayesian analysis. Pharmacol Res Off J Ital Pharmacol Soc 64(4):426Google Scholar
- 3.Jelliffe RW, Schumitzky A, Bayard D, Milman M, Van Guilder M, Wang X, Jiang F, Barbaut X, Maire P (1998) Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new ‘multiple model’ dosage design, Bayesian feedback and individualised target goals. Clin Pharmacokinet 34(1):57–77CrossRefPubMedGoogle Scholar
- 8.Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL, on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14 (6):498–509Google Scholar
- 13.Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O (2012) Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 55(3):381–390CrossRefPubMedGoogle Scholar
- 19.Wang T, Chen S, Sun J, Cai J, Cheng X, Dong H, Wang X, Xing J, Dong W, Yao H, Dong Y (2013) Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother 69(2):463–470CrossRefPubMedGoogle Scholar
- 24.Bonate PL (2005) Pharmacokinetic–pharmacodynamic modeling and simulation. Springer, New YorkGoogle Scholar
- 26.Holford N (2005) The Visual Predictive Check Superiority to Standard Diagnostic (Rorschach) Plots. Paper presented at the PAGE 14, Pamplona, Spain. http://www.page-meeting.org/?abstract=738. Accessed 1 Dec 2015
- 27.Continuous National Health and Nutrition Examination Survey. National Center for Health Statistics Center for Disease Control and Prevention. http://wwwn.cdc.gov/nchs/nhanes/search/nhanes_continuous.aspx. Accessed 29 April 2015
- 31.(CDC). CfDCaP (2014) National Health and Nutrition Examination Survey Data. National Center for Health Statistics (NCHS), Hyattsville, MDGoogle Scholar
- 32.Al-Sallami H, Goulding A, Taylor R, Grant A, Williams S, Duffull S (2011) A semi-mechanistic model for estimating fat free mass in children. Paper presented at the Population Analysis Group Europe, Athens. http://www.page-meeting.org/page/page2011/PAGEPosters.pdf. Accessed 1 Dec 2015
- 33.Development Core Team R (2014) R: a language and environment for statistical computing. R Found Stat Comput, ViennaGoogle Scholar
- 36.Gilbert DN The Sanford guide to antimicrobial therapy 2011. Antimicrobial Therapy, Inc., SperryvilleGoogle Scholar
- 44.Hoenigl M, Duettmann W, Raggam RB, Seeber K, Troppan K, Fruhwald S, Prueller F, Wagner J, Valentin T, Zollner-Schwetz I, Wölfler A, Krause R (2013) Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother 57(7):3262–3267CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr, Thakker DR (2010) In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos 38(1):25–31CrossRefPubMedPubMedCentralGoogle Scholar